Upadacitinib Led to Sustained, 140-Week Improvements for Ato

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

Related Keywords

United States , Chicago , Illinois , American , Linkedin Vimalh Prajapati , Vimalh Prajapati , , University Of Calgary , American Academy Of Dermatology , Drug Administration , Atopic Dermatitis , Annual Meeting , Eczema Area , Severity Index , Dermatology Life Quality Index , Worst Pruritus Numerical Rating Scale , Total Symptom Score , Skin Pain , Patient Oriented Eczema Measure , Daily Activities , Emotional State ,